Supernus Pharmaceuticals SUPN Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's pre-tax income?
- Supernus Pharmaceuticals (SUPN) reported pre-tax income of -$5.95M in Q1 2026.
- How has Supernus Pharmaceuticals's pre-tax income changed year-over-year?
- Supernus Pharmaceuticals's pre-tax income decreased by 2.0% year-over-year, from -$5.83M to -$5.95M.
- What is the long-term trend for Supernus Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's pre-tax income has grown at a -9.5% compound annual growth rate (CAGR), from $73.18M to -$49.03M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.